Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor

Planegg/Martinsried, May 2, 2024. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the...

Related Keywords

Taiwan ,South Korea ,Japan ,New York ,United States ,Australia ,Pamela Keck ,Planegg Martinsried ,European Patent Office ,Prime Standard ,End To Technology ,End To Platform ,